Back to Journals » OncoTargets and Therapy » Volume 8

Comparative study on individual aromatase inhibitors on cardiovascular safety profile: misleading analysis and doubtful methodology

Authors Guo W , Li L

Received 25 October 2015

Accepted for publication 29 October 2015

Published 20 November 2015 Volume 2015:8 Pages 3465—3466

DOI https://doi.org/10.2147/OTT.S99141

Checked for plagiarism Yes

Editor who approved publication: Professor Daniele Santini



Wenqin Guo, Lang Li

Department of Cardiology, The First Affiliated Hospital of Guangxi Medical University, Nanning, People’s Republic of China


Zhao et al have presented the result of the relative cardiovascular safety profile in using anastrozole, letrozole, and exemestane to treat the postmenopausal estrogen receptor-positive breast cancer, in which fatal or nonfatal myocardial infarction is the outcome measure and ten randomized controlled trials are used as the data sources.1 We congratulate and applaud their important work, but there are some issues of concern. 

 

View original article by Zhao et al 

Dear editor

Zhao et al have presented the result of the relative cardiovascular safety profile in using anastrozole, letrozole, and exemestane to treat the postmenopausal estrogen receptor-positive breast cancer, in which fatal or nonfatal myocardial infarction is the outcome measure and ten randomized controlled trials are used as the data sources.1 We congratulate and applaud their important work, but there are some issues of concern.

First, the difference in duration of adjuvant tamoxifen therapy among the studies led to heterogeneity and inconsistency. For instance, the duration of tamoxifen therapy was 2 years in the TEAM (Tamoxifen Exemestane Adjuvant Multinational) trial, whereas it was 5 years in the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial. In fact, the duration of tamoxifen therapy is relevant to toxicity. The practice of “lumping” cotreatments together generally makes no sense in clinical practice.2 In addition, the author regarded the sequential therapy (tamoxifen for 2 years followed by anastrozole for 3 years) or the extended adjuvant therapy (tamoxifen for 5 years followed by anastrozole for 3 years) as the anastrozole group, which was misleading. In fact, the tamoxifen would have the “crossover” effect even after the completion of the 2-, 3-, or 5-year treatment period. Instead, the author should have considered comparing the safety prolife among the initial aromatase inhibitor therapy, sequential therapy, and extended therapy, which would be of a more meaningful clinical significance.

Second, the authors failed to include three relevant randomized controlled trials in their meta-analysis, although they apparently met their inclusion criteria.35

Third, there was one important methodological issue in this review. The reporting of the inconsistency between the direct and indirect comparison is laudable in a network meta-analysis. However, this review did not describe the methodology of the inconsistency analysis in the “Statistical analysis” section.

Finally, in Figure 3, it was described that both severe and total cardiovascular risk deviance information criterion values were <200, which means that the calculated results were convincible. We are interested in the source of this perspective. In addition, the methodology of model fit was not confirmed in the “Statistical analysis” section.

Disclosure

The authors report no conflicts of interest in this communication.


References

1.

Zhao X, Liu L, Li K, Li W, Zhao L, Zou H. Comparative study on individual aromatase inhibitors on cardiovascular safety profile: a network meta-analysis. Onco Targets Ther. 2015;8:2721–2730.

2.

Ades AE, Caldwell DM, Reken S, Welton NJ, Sutton AJ, Dias S. Evidence synthesis for decision making 7: a reviewer’s checklist. Med Decis Making. 2013;33(5):679–691.

3.

Bonneterre J, Thurlimann B, Robertson JF, et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex randomized group efficacy and tolerability study. J Clin Oncol. 2000;18(22):3748–3757.

4.

Nabholtz JM, Buzdar A, Pollak M, et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol. 2000;18(22):3758–3767.

5.

Paridaens RJ, Dirix LY, Beex LV, et al. Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group. J Clin Oncol. 2008;26(30):4883–4890.

Creative Commons License © 2015 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.